Gennex Laboratories MD, chairman and AGM
BSE: 531739Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 28 Oct 2026. Previous close ₹8.88.
28 Oct: open ₹8.80, high ₹9.21, low ₹8.80
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹221 Cr2,248th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 12.03
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.99
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,86,354
Gennex Laboratories' chairperson and managing director is ARIHANT BAID, as filed for the quarter to Jun 2026. Its latest annual general meeting was on 30 Sep 2026.
Gennex Laboratories board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorARIHANT BAID
6 directors3 independent1 executive2 non-executive
- ARIHANT BAID · Chairperson and managing directorExecutive · joined May 2012 · reappointed Sep 2024 · 60 months as independent · 1 listed board
- DILIP RAJ SINGHVIIndependent · joined Oct 2024 · 60 months as independent · 2 listed boards · 2 as independent · 4 committee seats, 2 as chair
- AVASARALA RANGA RAO PANTULUNon-executive · joined Dec 2020 · reappointed Sep 2024 · 1 listed board · 2 committee seats
- AMUDALA SREERAMULU NAGESWAR RAOIndependent · joined Dec 2020 · 60 months as independent · 1 listed board · 1 as independent · 2 committee seats
- SANDEEP KUMAR DAGANon-executive · joined May 2025 · 1 listed board
- KHUSHBU KACHHAWAIndependent · joined Feb 2026 · 60 months as independent · 2 listed boards · 2 as independent · 2 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
3 directors who left
- SHILPA BUNG, left 14 Feb 2026: Others
- Dr.S.CH. DHARMA RAO, left 30 May 2025: Others
- MOHAMMED KHALEEQUR RAHMAN, left 14 Feb 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 24 Jun 20266 of 6 present3 independent · 24 days in between
- 30 May 20266 of 6 present3 independent · 43 days in between
- 16 Apr 20266 of 6 present3 independent · 60 days in between
- 14 Feb 20265 of 6 present2 independent
Audit Committee
Chair DILIP RAJ SINGHVI
AMUDALA SREERAMULU NAGESWAR RAO, AVASARALA RANGA RAO PANTULU, KHUSHBU KACHHAWA
- 30 May 20264 of 4 present3 independent · 104 days in between
- 14 Feb 20263 of 4 present2 independent
Nomination and remuneration committee
Chair DILIP RAJ SINGHVI
AMUDALA SREERAMULU NAGESWAR RAO, AVASARALA RANGA RAO PANTULU, KHUSHBU KACHHAWA
- 30 May 20264 of 4 present3 independent · 104 days in between
- 14 Feb 20263 of 4 present2 independent
Stakeholders Relationship Committee
Chair DILIP RAJ SINGHVI
AMUDALA SREERAMULU NAGESWAR RAO, AVASARALA RANGA RAO PANTULU, KHUSHBU KACHHAWA
- 30 May 20264 of 4 present3 independent · 104 days in between
- 14 Feb 20263 of 4 present2 independent
RIGHTS ISSUE COMMITTEE
Chair ARIHANT BAID
DILIP RAJ SINGHVI, AMUDALA SREERAMULU NAGESWAR RAO
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- R PUGALIA & COMPANYPeer-review certificate valid to Aug 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Gennex Laboratories AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.
Annual general meeting, 30 Sep 2026
81,565 shareholders on the register on 23 Sep 2026; present: 5 promoters and 42 others; votes counted by SWEETY KAPOOR / SWEETY KAPOOR.The company's voting result
Adoption of financial statements: (a) The Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the Reports of the Board of Directors and the Auditors thereon; (b) The Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the Report of the Auditors thereon.MoreLess
Ordinary99.97% for0.03% againstAgainst: promoters 0.00% · institutions 0.00% · other public 2.01%
Turnout: all 11.95% · promoters 49.81% · institutions 0.00% · other public 0.24%
- Appointment of Director in place of Dr. Avasarala Ranga Rao Pantulu (DIN: 09003006) who retires by rotation and, being eligible, seeks re-appointmentOrdinary99.87% for0.13% against
Against: promoters 0.00% · institutions 0.00% · other public 8.39%
Turnout: all 11.95% · promoters 49.81% · institutions 0.00% · other public 0.24%
- Appointment of Mr. Dipankar Dasgupta (DIN: 05312364) as an Independent Director (Non- Executive) of the CompanySpecial99.87% for0.13% against
Against: promoters 0.00% · institutions 0.00% · other public 8.55%
Turnout: all 11.95% · promoters 49.81% · institutions 0.00% · other public 0.24%
- Ratification of remuneration of M/s. Sai Krishna & Associates, Cost Accountants (Regn No. 001742) for the financial year ending 31st March, 2027Ordinary99.87% for0.13% against
Against: promoters 0.00% · institutions 0.00% · other public 8.39%
Turnout: all 11.95% · promoters 49.81% · institutions 0.00% · other public 0.24%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.
Mutual fund votes, meeting of 30 Sep 2026, 2 fund houses
Adoption of financial statements: (a) The Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the Reports of the Board of Directors and the Auditors thereon; (b) The Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the Report of the Auditors thereon.MoreLess
2 for0 against- Appointment of Director in place of Dr. Avasarala Ranga Rao Pantulu (DIN: 09003006) who retires by rotation and, being eligible, seeks re-appointment2 for0 against
- Appointment of Mr. Dipankar Dasgupta (DIN: 05312364) as an Independent Director (Non- Executive) of the Company2 for0 against
- Ratification of remuneration of M/s. Sai Krishna & Associates, Cost Accountants (Regn No. 001742) for the financial year ending 31st March, 20272 for0 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Tax disputes
Reported in the filing for the quarter to Jun 2026.
- Tax disputeAssessment Unit, Income Tax DepartmentSince 8 May 2026The Company has submitted reply on 05-06-2026. Awaiting further communication from the Department.At the filing before: New Intimation under Section 271AAC(1) of the Income Tax Act, 1961 towards Penalty for AY 2017-18.
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Sep 2025. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesJul 2025 | 6.64 | The proceeds of the issue will be utilized to modernise and expand its existing manufacturing facilities to cater the enormous demands of its products in the domestic and global markets. To set-up new pharmaceuticals API manufacturing facility and/or acquiring existing manufacturing facilities in the same line of operations. To meeting working capital requirement. To set-up research and development unit for exploring new products. To file Drug Master Files with various regulated and semi regulated overseas markets. To set-up wholly owned foreign subsidiary and make investment in the same. To make investment in existing/new subsidiary Companies for expanding manufacturing/marketing activities. To meet requirements of the Company for general corporate purpose. Till the funds are effectively utilized for the above mentioned purposes, the Board shall keep the funds in the fixed deposits with Banks/units of the mutual funds and/or other short term financial instruments. | 6.64 | 6.64 | No |
| Preferential IssuesJul 2025 | 6.08 | The proceeds of the issue will be utilized to modernise and expand its existing manufacturing facilities to cater the enormous demands of its products in the domestic and global markets. To set-up new pharmaceuticals API manufacturing facility and/or acquiring existing manufacturing facilities in the same line of operations. To meeting working capital requirement. To set-up research and development unit for exploring new products. To file Drug Master Files with various regulated and semi regulated overseas markets. To set-up wholly owned foreign subsidiary and make investment in the same. To make investment in existing/new subsidiary Companies for expanding manufacturing/marketing activities. To meet requirements of the Company for general corporate purpose. Till the funds are effectively utilized for the above mentioned purposes, the Board shall keep the funds in the fixed deposits with Banks/units of the mutual funds and/or other short term financial instruments. | 6.08 | 6.08 | No |